Antidepressants revolutionized the treatment of depression over 50 years ago, but symptoms persist for approximately one-third of patients, even after trying two or more antidepressants.  This form of depression is commonly known as treatment-resistant depression (TRD).

Despite its name, TRD can usually be treated, but finding what works isn’t always easy.

As the mental health landscape continues to evolve, patient stories and treatment options are at the forefront of discussions. The National Press Foundation will bring together health and psychology experts – as well as a journalist who has written about her own treatment-resistant depression – on a panel from 12-1 p.m. ET on April 30 to answer your questions on this issue.

While treatment-resistant depression (TRD) has made headlines recently, particularly when it comes to ketamine treatments, there is much more for journalists and the public to know.

In addition to ketamine, scientists are researching, transcranial magnetic stimulations, deep brain stimulation and psilocybin. But there’s no one-size-fits-all solution.

To get answers to your questions on treatment-resistant depression and learn how to cover this complex medical condition with depth and nuance, register now for NPF’s virtual briefing on April 30, 12-1 p.m. ET.

This webinar is sponsored by Johnson & Johnson. NPF is solely responsible for its content.